Hebei Senlang Biotechnology Co., Ltd., established in 2016, is a high-tech biopharmaceutical enterprise focusing on the R&D and application of new cell therapy technologies, and is committed to the precise treatment of malignant tumors. The founder and chief scientist of the company, Dr. Jianqiang Li, has many years of overseas research and development experience. He has served as a senior scientist in well-known research and development institutions such as the City of Hope Cancer Research Center in Los Angeles and the Fred Hutchinson Cancer Research Center in Seattle. The company is headquartered in Shijiazhuang High-tech Zone, and has built a CAR-T (chimeric antigen receptor T cell) research center with an area of 16,000 square meters. The company has an efficient cell therapy innovation technology platform, with an independent product research and development system covering the whole process of virus, plasmid, cell culture, detection, clinical trials, etc. To CD7 CAR-T, combination (Combo) CAR-T, universal CAR-γδT and a number of leading products for solid tumors, for the treatment of acute lymphoblastic leukemia, lymphoma and other major hematological tumors and liver cancer and other solid tumors. Relevant achievements have been highly recognized by international peers, and have been published in many journals such as the industry authoritative journal "Blood" (impact factor 23.629). Report at the annual meeting.